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Abstract
Background & Objective: Echinococcosis is still a common health problem. The aim of  this study was to discuss our 8-year data 
in terms of  diagnosis, treatment and follow-up of  cystic Echinococcosis.
Methods: A total of  178 patients who had hydatid cyst were analyzed retrospectively from the hospital records. The diagnosis 
of  hydatid cyst was based on clinical-serological and radiological findings. Treatment response was evaluated with clinical, ra-
diological and serological findings.
Results: A total of  178 medical records were evaluated; the male:female ratio was 0.73 and mean age 44.6±16.9 years. The 
most common symptom was abdominal pain (94, 52.8%). The mean cyst size was 9.5±3.9 cm. Eosinophilia was significantly 
higher in patients with complicated cyst (35.3%) (p=0.002). The average duration of  hospitalization in surgical patients was 
shorter than non-surgical patients (p=0.026). There was no significant correlation between the preference of  scolicidal agent 
(hypertonic saline, H2O2, povidone iodine) and recurrence in patients who underwent surgery (p>0.05). There was no signifi-
cant difference between the patients who underwent radical and conservative surgery in terms of  complication and recurrence 
(p=0.077, p=0.557). No significant difference was found between percutaneous and surgical treatment in terms of  complication 
and recurrence (p=0.264, p=0.276).
Conclusion: Even though considerable progress has been made, uncertainties remain in the diagnosis and treatment of  Echino-
coccosis. Hence, standardized diagnostic and treatment procedures should be established with well-designed studies.
Keywords: Echinococcosis, hydatid cyst, diagnosis, treatment.
DOI: https://dx.doi.org/10.4314/ahs.v19i3.17
Cite as: Sen P, Demirdal T, Nemli SA. Evaluation of  clinical, diagnostic and treatment aspects in hydatid disease: analysis of  an 8-year 
experience. Afri Health Sci. 2019;19(3): 2431-2438. https://dx.doi.org/10.4314/ahs.v19i3.17
Corresponding author: 
Pinar Sen, 
Izmir Katip Celebi University 






Echinococcosis is a zoonotic disease in areas where agricul-
ture and livestock are common such as Mediterranean re-
gion, SouthWestern United States, Latin America, Middle 
East, China and Africa1,2. It is reported that the incidence 
in humans can reach 50 per 100,000 person-years and 
prevalence increases from 5% to 10% in endemic coun-
tries3. In addition, no cases have been reported in An-
tartica until now, while New Zeland, Cyprus, Tasmania 
and Iceland could be eliminated through effective control 
programs4.
Cystic echinococcosis (hydatid disease) is an infection caused 
by the cestode may cause hydatid unilocular cystic dis-
ease in humans3. The feces of  tapeworm–infected defin-
itive-host is responsible for the contamination of  envi-
ronment. Infecting eggs are taken by fecal-oral route in 
intermediate hosts2. The parasite eggs may remain infec-
tive for weeks because they are resistant to environmental 
conditions5-9. Therefore, it is possible to transmit without 
direct contact with infected-host. It has not been demon-
strated transmission between humans yet7,10.
Hydatid disease affects both developing countries and 
people traveling to these endemic regions2,3. Therefore, 
it is widespread throughout the world and causes about 
$3 billion dollars in financial costs including livestock 
losses and treatment each year11,12.  The disease may be 
spontaneously limited or it may also be observed with 
complications1,13. Unfortunately, the diagnosis is usually 
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incidental and particularly atypical settlements may es-
cape from attention which leads to increase in morbidity 
and mortality2. Also, there are different opinions about 
treatment and follow-up and there is not yet a common 
consensus on this issue6,14. The aim of  this study was to 
discuss our 8-year data in terms of  diagnosis, treatment 
and follow-up of  cystic Echinococcosis with the context of  
the literature.
Methods
We conducted a retrospective study at the Katip Cele-
bi University, Ataturk Training and Research Hospital, a 
1055-bed tertiary referral care center in Izmir, Turkey. A 
total of  204 patients who had hydatid cyst between Janu-
ary 2009 and May 2016 were analyzed retrospectively from 
the hospital records. The study protocol was approved by 
our local ethics committee. Twenty-six of  these patients 
were excluded from the study due to the absence of  a 
definitive diagnosis or as they had a different diagnosis. 
One hundred seventy-eight patients were included in the 
study. The diagnosis of  hydatid cyst was based on clini-
cal-serological and radiological findings. The diagnosis of  
patients who underwent surgery was confirmed by patho-
logical examination. The demographic data, symptoms, 
physical examination findings, laboratory values, diagnos-
tic methods, cyst details (localization and size), complica-
tions, treatment, length of  stay, follow-up, recurrence and 
all deaths were recorded. X-ray, ultrasonography (USG), 
computed tomography (CT) and magnetic resonance 
imaging (MRI) were performed before the treatment in 
terms of  differential diagnosis and screening. In asymp-
tomatic patients, diagnosis was considered as the result of  
imaging studies for other reasons.
Albendazol (10 mg/kg/day) was used in medical treat-
ment. Albendazole administration was carried out as two 
doses daily for 3 months. The hydatid cysts were clas-
sified according to the WHO Informal Working Group 
on Echinococcosis (WHO-IWGE) classification system by 
USG15. Percutaneous treatment of  the hydatid cyst with 
the PAIR (Puncure, Aspiration, Injection, Re-aspiration) 
technique was used on appropriate indications The pro-
cedure was performed under USG guidance by interven-
tional radiology. Firstly, the cyst contents were drained, a 
hypertonic saline was instilled into the cyst and left into 
the cavity for 15 minutes, then re-aspirated after the sepa-
ration of  germinative membrane. Surgical procedure was 
performed according to the cyst location, cyst structure 
and surgeon's preference. Hypertonic saline, povidone 
iodine or H2O2 was used as scolicidal agent during sur-
gery. Treatment response was evaluated with clinical, ra-
diological and serological findings. Clinical recovery of  
patients with the collapse, calcification or absence of  cyst 
was evaluated as treatment success. The acquisition of  
new cyst in same or different organs and same or larger 
cyst size after treatment was evaluated as recurrence.
Statistical analyses were performed using the SPSS soft-
ware version 24. The variables were investigated using the 
Kolmogorov-Smirnov test. Descriptive analyses were pre-
sented using means and standard deviations for normally 
distributed variables. Student’s t-test was used to compare 
these parameters. The Mann-Whitney U test was used to 
compare of  non-parametric parameters. The Chi-square 
test or Fisher’s exact test was used for the comparison of  




A total of  178 medical records were evaluated; the male: 
female ratio was 0.73 (75 men, 103 women) and mean 
age 44.6±16.9 years (range 4-81 years) at the time of  di-
agnosis. Of  this patients, 88 (49.4%) lived in rural areas 
while 90 (50.6%) lived in urban areas. Six patients were 
under 18 years of  age. The number of  patients who were 
diagnosed as hydatid cyst was 53 in 2009, 23 in 2010, 11 
in 2011, 34 in 2012, 19 in 2013, 15 in 2014, 10 in 2015 
and 13 in 2016.
Clinical findings
The most common symptom was abdominal pain (94, 
52.8%). Other symptoms were nausea/vomiting (12, 
6.7%), upper abdominal bloating (7, 3.9%) and jaundice 
(7, 3.9%). In extrahepatic Echinococcal cases, there were 
different symptoms according to cyst location. There was 
a chest pain in 1 (0.5%) patient with cardiac Echinococcosis, 
palpable mass in 2 (1.1%) patients with Echinococcosis of  
extremity, urinary incontinence in 1 (0.5%) patient with 
spinal Echinococcosis, headache in 1 (0.5%) patient with in-
tracranial Echinococcosis. Seventy-three (41%) patients were 
asymptomatic and the diagnosis was made incidentally. 
On general physical examination, abdominal tenderness 
(18, 10.1%), palpable mass in the extremity (2, 1.1%) and 
hepatomegaly (1, 0.6%) were found. The physical ex-
amination was normal in the majority of  patients (157, 
88.2%).
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Laboratory findings
The initial laboratory profile revealed a mean leukocyte 
level of  8528.3±3092.8 K/uL, a mean erythrocyte sed-
imentation rate (ESR) of  31.2±23 mm/h. Leukocytosis 
was found in 12.9% of  the patients. Eosinophilia was de-
fined as at least 6% of  the leukocyte value on differential 
count, detected in 20.5% of  patients and mean count was 
5.4±8.7%.  Eosinophilia was significantly higher in pa-
tients with complicated cyst (rupture or fistula) (35.3%) 
(p=0.002). The sensitivity of  Echinococcal indirect hem-
agglutination test (IHAT) was 81.6% (40/49), indirect 
immunofluorescence test (IFAT) sensitivity was 73.7% 
(70/95) and enzyme-linked immunosorbent assay (ELI-
SA) sensitivity was 87.5% (147/168). USG was used as 
diagnostic test for 166 patients with hepatic cystic Echino-
coccosis and had 100% sensitivity. Endoscopic retrograde 
cholangiopancreatography (ERCP) was performed in 3 
patients who had cholestasis.
Imaging findings
The mean cyst size was 9.5±3.9 cm (range 3 to 20 cm) 
and 52 (29.2%) cysts were larger than 10 cm. Accord-
ing to the WHO-IWGE classification, 13.7% of  the cysts 
were type CE1, 37.3% were type CE2, 23.5% were type 
CE3 and 25.5% were type CE4 and CE5. The most com-
mon site of  cyst was liver (151, 84.8%). In 108 (60.7%) 
patients, cysts were located in the right lobe of  the liver 
and 18 (10.1%) patients had bilateral multiple liver cysts. 
Cyst localizations were shown in Table 1. There were 29 
(16.3%) patients with at least one complicated cyst. Com-
plications of  cyst were as follows; infected cyst (37.9%), 
biliary fistula (31%), compression of  bile ducts (24.1%), 
ruptured cyst (20.7%), duodenal fistula (6.9%). There 
was no significant difference between complicated and 
non-complicated cysts in terms of  age, gender, and cyst 
size (p=0.132, p=0.518, p=0.906 respectively).
Table 1. Cyst localizations 
 
Localizations n % 
Liver 151 84.8% 
Liver + lung 8 4.5% 
Liver + spleen 2 1.1% 
Liver + intraperitoneum 1 0.6% 
Liver + intraperitoneum + retroperitoneum 1 0.6% 
Liver + heart 1 0.6% 
Liver + pelvic cavity + transverse colon 1 0.6% 
Liver + lung + brain (right parietal lobe) 1 0.6% 
Isolated organ involvement     
Spleen 4 2.2% 
Kidney 2 1.1% 
Heart 1 0.6% 
Stomach 1 0.6% 
Thigh 1 0.6% 
Spinal (lumber) 1 0.6% 
Psoas muscle (right) 1 0.6% 
Cruris posterior 1 0.6% 
  
  
Table 1. Cyst l calizations 
 
L calizations n % 
Liver 151 84.8% 
Liver + lung 8 4.5% 
Liv r + spleen 2 1.1% 
Liver + intraperitoneum 1 0.6% 
Liver + intraperitoneum + retroperitoneum 1 0.6% 
Liver + heart 1 0.6% 
Li er + pelvic cavity + transverse colon 1 0.6% 
Liver + lu g + brain (right parietal lobe) 1 0.6% 
Isol ted organ involvement     
Spleen 4 2.2% 
Kidney 2 1.1% 
Heart 1 0.6% 
Stomach 1 0.6% 
Thigh 1 0.6% 
Spinal (lumber) 1 0.6% 
Psoas muscle (right) 1 0.6% 




One hundred and two (56.7%) patients underwent sur-
gery. Radical surgery was performed in 8 patients (4 peri-
cystectomy and 4 segmental liver resection) while the 
other patients underwent conservative surgery (partial 
cystectomy and drainage). Of  these patients who un-
derwent partial cystectomy, 7 of  them were treated with 
capitonnage, 13 patients with omentopexy and 2 patients 
with intraflexion. There was no significant difference 
between the patients who underwent radical or conser-
vative surgery in terms of  complication and recurrence 
(p=0.077, p=0.557). There was no significant correlation 
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between the preference of  scolicidal agent (hypertonic 
saline, H2O2, povidone iodine) and recurrence in patients 
who underwent surgery (p>0.05). The patients with ex-
trahepatic hydatid cyst were also surgically treated includ-
ing splenectomy (4), nephrectomy (2), ventriculotomy 
(1) and pericardiotomy (1), craniotomy and cyst extirpa-
tion (1). Patients with pulmonary hydatid disease were 
referred to the department of  cardiothoracic surgery at 
another hospital. Surgical morbidity was 34.3%. The sur-
gery-related complications were as follows; leakage of  
cyst fluid (17), hepatic injury (8), diaphragmatic laceration 
(4), eventration/evisceration (3), liver abscess (1), spleen 
abscess (1) and cyst rupture (1) (Table 2). The average 
duration of  hospitalization in surgical patients (11.9±8.3 
days) was shorter than non-surgical patients (80.6±30.3 
days) (p=0.026). The mean hospital stay in patients with-
out postoperative complications was 16 days, while in pa-
tients with complications was 26.2 days (p=0.715). Sur-
gical mortality was 0.9% (n=1). One patient with hepatic 
hydatid cyst died 1 month after surgery from biliary fistu-
la, liver abscess and peritonitis.
Percutaneous treatment results
PAIR was used in 49 (27.5%) patients. Procedure-related 
complications were observed in 9 (18.4%) patients. The 
complications of  PAIR were abscesses formation in the 
residual cavity (6), bile leakage (4), anaphylactic shock (1), 
cyst rupture (1), pleural effusion (1) and intracystic hem-
orrhage (1). No death occurred related to PAIR.
Watch-and-wait approach
The ‘watch-and wait’ approach was applied to 12 (6.7%) 
patients who had uncomplicated inactive cysts (10 hepatic 
and 2 splenic cysts). The diameter of  the cyst ranged be-
tween 2 and 10 cm (6.2±2.8 cm). The IFAT test was nega-
tive in all of  these patients, whereas the IHA test was pos-
itive in 2 patients. Mean follow-up was 33 months(range 
6-84 months). In follow-up, no reactivation or complica-
tion was observed serologically and radiologically.
Follow-up findings
The median follow-up was 19.1±24.9 months (range 
0-168 months). Seven of  the patients (3.9%) were lost 
to follow-up before the treatment. The treatment of  171 
patients who were followed up is shown in Table 2. 
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Chemotherapy  5.3% 
(9/171) 7.1±1.1 




































       * One patient with liver and spleen cysts underwent PAIR+surgery (splenectomy) 
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There were 89 (50%) patients followed longer than 12 
months and recurrence was found in 40/89 (44.9%) of  
these patients. A total recurrence rate was 28.6% (n=51) 
from the time of  initial diagnosis. All recurrences oc-
curred in the liver, additionally in 2 cases in the perito-
neum and in 1 case in the small intestine. The IFAT was 
performed in 16 of  51 patients with recurrence and was 
found positive in all of  these patients. USG and CT were 
used in detecting recurrence of  hydatid disease. No sig-
nificant difference was found between PAIR and surgi-
cal treatment in terms of  complication and recurrence 
(p=0.264, p=0.276). The mean duration of  albendazole 
treatment in patients with recurrence was shown in Table 
3.
    
Table 3. Duration of treatments according to the type of treatment and recurrence 
 











11.2±22.1 65±48.6 0.005 27.8±44 65.7±72.8 0.018 
Total 10.6±32.3 63.5±74.9 0.008 28.6±49.5 72.7±70.5 0.002 
 
* Kolmogorov-Smimov Z test was performed at the beginning of the analysis. We found that our data was not show normal distribution because 
the p value was smaller than 0.05. Therefore we used Mann Whitney U test which is non-parametric counterpart of the t-test. The mean and 
standard deviation (mean±SD) are given in the table and the p values belong to the Mann Whitney U test. 
Discussion
The worldwide incidence and prevalence of  Echinococcosis 
has decreased significantly as a result of  disease control 
programs in recent years16. Nevertheless, Echinococcosis is 
still a common health problem in developing countries, 
especially in rural areas2. Community-based studies have 
shown that the prevalence of  disease is between 1% and 
10% in endemic regions17. It has been reported that prev-
alence is higher in women and in middle age group as 
shown in our study3,17,18. It may be caused by gender roles 
such as closer contact with dogs, tending gardens, feeding 
or milking livestock in endemic areas and slow growth of  
the cyst hydatid.
The most common locations of  the Echinococcosis are liver 
(68-75%) and lung (15-22%)17-19. The right lobe of  the 
liver is affected more common than the left lobe3. More 
rarely, hydatid disease can occur anywhere in the body 
(5-10%), such as spleen, kidney, heart, bones, muscles, 
skin, abdominal or pelvic cavity, brain and ovaries 6,19. 
Although cysts are usually solitary in a single organ (about 
80%), the incidence of  multiple cysts or multiple organ 
involvement ranges from 10-15% depending on the par-
asite genotype and geographic region3,6,11. In our study, 
the hepatic hydatid cysts were usually solitary (84.8%) 
and were detected in the right lobe (60.7%). Two or more 
organ involvement was detected in 8.6% of  patients. In 
endemic areas, hydatid cyst should be kept in mind when 
a cystic lesion is detected anywhere in the body. If  the 
lesion is hydatid cyst, the liver and lung must be screened 
for primary involvement.
There are usually no symptoms in intact and small cysts, 
however symptoms may appear in growing cysts which 
compress the surrounding tissue (bilier tract, bronchus, 
major vessels, intestine) or in complicated cysts such as 
rupture, infection or anaphylaxis3,20,21. The most common 
symptom is upper abdominal pain for hepatic Echinococ-
cosis and cough for pulmonary Echinococcosis17. Atypical lo-
calizations in hydatid disease may present with different 
symptoms depending on which organ is involved2. In this 
study, abdominal pain was the most common complaint 
as expected in hepatic Echinococcosis, while different clini-
cal manifestations such as mass, urinary incontinence and 
headache were detected in hydatid disease with atypical 
localization. None of  our pulmonary hydatid disease pa-
tients had any symptoms and were detected by screening. 
This may be due to the fact that cough is ignored by pa-
tients with pulmonary hydatitosis and they are not seek-
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ing medical care for minor symptoms. In endemic areas, 
persistent abdominal pain and dry cough should be ques-
tioned in terms of  hydatid disease because symptoms are 
usually minor in Echinococcosis. These complaints should 
be investigated in terms of  hydatid disease if  symptoms 
do not resolve with symptomatic treatment. In addition, 
it is appropriate to evaluate the cystic lesions detected in 
endemic regions in terms of  hydatid cysts, because clini-
cal findings may be different in atypical presentation.
The diagnosis of  disease is mainly based on imaging re-
sults; epidemiological data, clinical findings and serolog-
ical tests are also helpful in confirming the diagnosis3,21. 
The combination of  imaging techniques with serological 
markers reveals a much higher detection rate in diagnosis 
of  Echinococcosis, therefore patients with symptoms should 
be evaluated with these two methods21. Although many 
new serological methods are mentioned in the literature, 
there is a limited number of  serological tests common-
ly used in endemic regions including IHAT, ELISA and 
IFAT3,6,18,21-23. Routine laboratory tests are usually non-
specific3. Eosinophilia has been reported in 20-34% of  
patients and may be associated with fluid leakage from 
cyst20. Eosinophilia is an important laboratory finding es-
pecially in complicated cysts as indicated in our study. Ad-
ditionally, highest sensitivity was obtained by ELISA in 
our study. We conclude that ELISA may be more useful 
in routine screening and follow-up of  patients.
USG, radiography, CT and MRI are usually used for diag-
nosis. Chest X-ray is often preferred for pulmonary echino-
coccosis screening and plain radiographs can also be used to 
detect calcified cysts which occur in the muscle or bone21. 
USG is the primary diagnostic procedure, for hepatic or 
extrahepatic echinococcal cysts, also helpful in the follow-up 
period and sensitivity ranges from 93-98%15,24. However, 
USG has lower sensitivity to detect smaller cysts21. The 
World Health Organization Informal Working Group on 
Echinococcosis (WHO-IWGE) published an international 
classification system in 2003 based on ultrasonographic 
imaging by modifying the Gharbi classification15. Accord-
ing to this classification, the cysts are divided into 6 stages 
in 3 different clinical groups. Class CE1 and CE2 cysts 
are active (viable), CE3 (CE3a and CE3b) is transitional 
group which contains degenerative cyst, CE4 and CE5 
are inactive group. Class CE3 cysts are divided into two 
groups; CE3a cysts responds to medical/percutaneous 
treatment while CE3b cysts are usually unresponsive. CT 
or MRI can be used if  USG is not appropriate in terms 
of  anatomic location. We concluded that USG sensitivi-
ty was 100% because the patients with symptomatic and 
large cysts referred to the hospital for diagnosis. In pa-
tients with small cysts, we often think that the diagnosis 
is frequently overlooked. We think that the use of  X-ray 
and USG is more cost-effective for scanning, especially in 
case of  suspicious cysts, -CT and MRI should be applied 
in selected cases in terms of  differential diagnosis.
The recommended methods for treatment of  cystic 
Echinococcosis are surgery, percutaneous procedures, an-
ti-infective drug treatment and observation (watch and 
wait)25. It is unclear which method is superior because of  
a lack of  randomized controlled trials comparing these 
methods21,22. Although surgery is indicated as the main 
treatment for hydatid disease, it becomes an alternative 
method due to the successful outcome of  less invasive 
approaches6,22. Therefore, surgery is especially applied to 
multivesicular cysts (CE2 and CE3b) which are not suit-
able for percutaneous interventions, cysts larger than 10 
cm and complicated cysts21,22,26,. PAIR is recommended 
for all CE1 and CE3a cysts that >5cm combined with 
medical treatment or <5 cm which unresponsive to med-
ical treatment5,6,21,22,25. We showed that PAIR or surgical 
choice did not cause a significant difference in the de-
velopment of  complication or recurrence. Therefore, 
choosing less invasive procedure for the appropriate indi-
cation may be a more rational approach.
Benzimidazoles (albendazole, mebendazole) are used in 
medical treatment of  Echinococcosis21,22,24,25. In recent years, 
albendazole is preferred because it is reported to be more 
effective than mebendazole6,19-21. Apart from albendazole, 
it has also been reported that different antiparasitic drugs 
such as praziquantel, nitazoxanide and -ivermectin are 
used alone or in combination for the treatment of  Echino-
coccosis19,21,22,24. However, for each stage of  cysts, random-
ized controlled trials should be performed comparing the 
results of  treatment with benzimidazole to different op-
tions19,21,24.
Spillage of  the cyst fluid into the abdominal cavity during 
surgery or PAIR may cause secondary (recurrent) Echino-
coccosis21,22. Although duration of  prophylaxis is not clearly 
defined by controlled studies, medical prophylaxis is gen-
erally recommended for 1 day-1 month before surgery 
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and 1 month-2 months after surgery to prevent recur-
rence25,26. Albendazole administration is recommended 
for 4 hours before puncture and 1 months after puncture 
to prevent PAIR related recurrence or anaphylaxis22,25,27. 
The data presented in our study with very wide standard 
deviation suggest that some patients have received more 
than 30 days; others have received less than 30 days. The 
considerable variability in albendazole administration may 
be due to the application of  different treatment protocols 
in different clinics. This could also explain the recurrence 
rate, higher than those found in other studies28. We con-
clude that the use of  peroperative albendazole, which has 
been shown in some studies that reduce complications 
and recurrence, should be routinely used in all interven-
tional procedures.
Routine USG scan is recommended every 3 to 6 months 
in the first 2 years, and then once a year at least 3 to 5 
years in terms of  recurrence6,25,27. Since serologic tests 
alone cannot distinguish recurrent or residual disease, it 
is recommended that serologic tests should be combined 
with imaging methods in the follow-up of  patients6. Fur-
ther prospective studies are required to make decision 
about the duration of  prophylaxis.
Conclusion
Even though considerable progress has been made, un-
certainties remain in the diagnosis and treatment of  Echi-
nococcosis. Imaging methods may not be easily accessible 
in resource poor settings even though they are essential 
for diagnosis, furthermore imaging techniques may not 
recognize early-stage cysts. Therefore new serodiagnos-
tic tests that can be widely used and has high sensitivity 
and specificity should be defined. The stage-specific ap-
proach recommended by WHO-IWGE should be used 
more widely in clinical practice since it is also a guide for 
the treatment option in Echinococcosis21. Clinical trial data 
that systematically assesses current treatments isnot avail-
able and there is no ideal treatment option. Hence, stan-
dardized diagnostic and treatment procedures should be 
established with well-designed studies. In addition, new 
strategies must be determined in order to eliminate the 
disease in collaboration with policy makers and veterinar-
ians.
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